Description:
A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the
Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in
Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer
Title
- Brief Title: A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
- Official Title: A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer
Clinical Trial IDs
- ORG STUDY ID:
D933IC00003
- NCT ID:
NCT03459846
Conditions
- Urinary Bladder Neoplasms
Interventions
Drug | Synonyms | Arms |
---|
Durvalumab | | Arm 1: Durvalumab/Placebo |
Olaparib | | Arm 2: Durvalumab/Olaparib |
Placebo | | Arm 1: Durvalumab/Placebo |
Purpose
A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the
Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in
Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer
Detailed Description
This is a Phase II, randomized, double-blind, placebo controlled, multi-center, comparative
global study to determine the efficacy and safety of durvalumab + olaparib combination
therapy versus durvalumab + placebo (durvalumab monotherapy) as first-line treatment in
patients ineligible for platinum-based chemotherapy with unresectable Stage IV urothelial
cancer (UC).
Trial Arms
Name | Type | Description | Interventions |
---|
Arm 1: Durvalumab/Placebo | Experimental | Durvalumab 1500 mg intravenous (IV) every 4 weeks (q4w) starting on week 1 day 1/Placebo orally (PO) twice a day (BID) starting on week 1 day 1. | |
Arm 2: Durvalumab/Olaparib | Experimental | Durvalumab 1500 mg IV q4w starting on week 1 day 1/Olaparib PO 300 mg BID adjusted based on patient's creatinine clearance. | |
Eligibility Criteria
Inclusion criteria:
1. Provision of signed and dated, written ICF
2. Histologically or cytologically documented TCC/UC of the urothelium (including renal
pelvis, ureters, urinary bladder, and urethra) also meeting the following:
Unresectable, Stage IV disease; No prior systemic therapy for unresectable, Stage IV
disease.
3. Ineligible for platinum-based chemotherapy defined as (i) in the opinion of the
Investigator, unfit for carboplatin-based chemotherapy and (ii) meeting one of the
following criteria: CrCl <60 mL/min calculated by Cockcroft-Gault equation; Common
Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 audiometric hearing loss (25
dB in 2 consecutive wave ranges); CTCAE Grade ≥2 peripheral neuropathy; New York Heart
Association Class III heart failure; ECOG 2.
4. Known tumor HRR mutation status prior to randomization.
5. World Health Organization (WHO)/ECOG performance status of 0, 1, or 2.
6. Patients with at least 1 RECIST 1.1 target lesion at baseline.
7. Ability to swallow oral medications.
8. Evidence of post-menopausal status, or negative urinary or serum pregnancy test for
female pre-menopausal patients.
Exclusion criteria
1. Active or prior documented autoimmune or inflammatory disorders.
2. Other invasive malignancy within 5 years before the first dose of the IP.
3. Major surgical procedure within 28 days prior to the first dose
4. Brain metastases or spinal cord compression unless the patient's condition is stable
and off steroid for at least 14 days
5. History of active primary immunodeficiency.
6. Active infection including tuberculosis (TB)
7. History of allogenic organ transplantation.
8. Uncontrolled intercurrent illness
9. Prior exposure to a PARP inhibitor or immune-mediated therapy.
10. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment.
11. Current or prior use of immunosuppressive medication within 14 days before the first
dose of the IP.
12. No radiation therapy is allowed, unless it is (1) definitive radiation that had been
administered at least 12 months prior; (2) palliative radiation to the brain, with
associated criteria for stability or lack of symptoms; or (3) palliative radiation to
painful bony lesions (this must comprise less than 30% of the bone marrow) or
symptomatic pelvic soft tissue mass(es).
13. Receipt of live attenuated vaccine within 30 days prior to the first dose of the IP.
14. Patients with a known hypersensitivity to durvalumab, olaparib, or any of the
excipients of the products.
15. Female patients who are pregnant or breastfeeding or male or female patients of
reproductive potential who are not willing to employ effective birth control from
screening to 90 days after the last dose of durvalumab.
Maximum Eligible Age: | 130 Years |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | The efficacy of Durvalumab+Olaparib combination therapy compared to Durvalumab + Placebo in terms of Progression-Free Survival (PFS) in patients with Platinum ineligible bladder cancer |
Time Frame: | 2 years |
Safety Issue: | |
Description: | |
Secondary Outcome Measures
Measure: | The efficacy of Durvalumab+Olaparib combination therapy compared to Durvalumab + Placebo in terms of Overall survival (OS) in patients with Platinum ineligible bladder cancer |
Time Frame: | 4 years |
Safety Issue: | |
Description: | |
Measure: | The efficacy of Durvalumab+Olaparib combination therapy compared to Durvalumab + Placebo in terms of Duration of response (DoR) in patients with Platinum ineligible bladder cancer |
Time Frame: | 2 years |
Safety Issue: | |
Description: | |
Measure: | The efficacy of Durvalumab+Olaparib combination therapy compared to Durvalumab + Placebo in terms of Objective Response Rate (ORR) in patients with Platinum ineligible bladder cancer |
Time Frame: | 2 years |
Safety Issue: | |
Description: | |
Measure: | The efficacy of Durvalumab+Olaparib combination therapy compared to Durvalumab + Placebo in terms of Progression-Free Survival (PFS) in patients with Platinum ineligible bladder cancer with homologous recombination repair mutated (HRRm) subgroup |
Time Frame: | 2 years |
Safety Issue: | |
Description: | |
Measure: | The efficacy of Durvalumab+Olaparib combination therapy compared to Durvalumab + Placebo in terms of Progression free at 6 months (PFS6) in patients with Platinum ineligible bladder cancer |
Time Frame: | 2 years. |
Safety Issue: | |
Description: | |
Measure: | The pharmacokinetics (PK) of durvalumab and olaparib as determined by trough concentration |
Time Frame: | Concentration of durvalumab and olaparib will be assessed three times, in Cycle 1 (each cycle is 28 days), 2 and 4. Additional assessments at Day 30 post last dose for olaparib, 3 months post last dose for durvalumab. |
Safety Issue: | |
Description: | |
Measure: | Presence of anti-drug antibodies (ADA) for durvalumab |
Time Frame: | ADA for durvalumab will be assessed three times, in Cycle 1(each cycle is 28 days), 2 and 4, and 3 and 6 months post last dose of durvalumab. |
Safety Issue: | |
Description: | |
Measure: | Patient reported outcome (PRO) including Global health status/Quality of Life (QoL), assessed through questionnaire - European Organisation for Research and Treatment of Cancer 30-item core quality of life questionnaire (EORTC QLQ-C30) |
Time Frame: | PRO:Global health status assessment on day of first dose and every 4 weeks until 3 months post treatment discontinuation. |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Active, not recruiting |
Lead Sponsor: | AstraZeneca |
Trial Keywords
- Urinary Bladder Neoplasms
Last Updated
August 24, 2021